A Study in Subjects With Moderate Atopic Dermatitis
Status:
Completed
Trial end date:
2018-06-29
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, vehicle-controlled study to evaluate the safety and
efficacy of ALX-101 Gel 1.5% and 5% and a matching ALX-101 Gel Vehicle when applied topically
twice daily for 42 days to adult and adolescent subjects with moderate atopic dermatitis.